重症肌无力发病机制及康复训练治疗研究进展

doi:10.3969/j.issn.1006-6233.2024.01.034

摘要
图/表
参考文献
相关文章 (15)

[1] Antonini G,Habetswallner F,Inghilleri M,et al.Real world study on prevalence,treatment and economic burden of myasthenia gravis in Italy[J].Heliyon,2023,9(6):16367.
[2] Wartmann H,Hoffmann S,Ruck T,et al.Incidence,prevalence,hospitalization rates,and treatment patterns in myasthenia gravis:a 10-year real-world data analysis of german claims data[J].Neuroepidemiology,2023,57(2):121-128.
[3] Phillips WD,Vincent A.Pathogenesis of myasthenia gravis:update on disease types,models,and mechanisms[J].F1000Res,2016,5:(1000):1513.
[4] Evoli A,Alboini PE,Damato V,et al.Myasthenia gravis with antibodies to MuSK:an update[J].Ann N Y Acad Sci,2018,1412(1):82-89.
[5] Huda S,Cao M,De Rosa A,et al.SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody[J].Neurol Neuroimmunol Neuroinflamm,2019,7(1):645.
[6] 常婷.中国重症肌无力诊断和治疗指南(2020版)[J].中国神经免疫学和神经病学杂志,2021,28(1):1-12.
[7] 于建奇,杨胜波.Agrin-LRP4-MuSK和Wnt信号通路对乙酰胆碱受体发育、聚集及稳定的调控[J].解剖学杂志,2015,38(2):229-231.
[8] Rodriguez Cruz PM,Cossins J,Cheung J,et al.Congenital myasthenic syndrome due to mutations in MUSK suggests that the level of MuSK phosphorylation is crucial for governing synaptic structure[J].Hum Mutat,2020,41(3):619-631.
[9] Go GW,Mani A.Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis[J].Yale Biol Med,2012,85(1):19-28.
[10] Barik A,Lu Y,Sathyamurthy A,et al.LRP4 is critical for neuromuscular junction maintenance[J].Neurosci.2014;34(42):13892-13905.
[11] Shen C,Lu Y,Zhang B,et al.Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis[J].Clin Invest,2013,123(12):5190-5202.
[12] Binks S,Vincent A,Palace J.Myasthenia gravis:a clinical-immunological update[J].Neurol,2016,263(4):826-834.
[13] Bhibhatbhan A,Kline G,Vincent A,et al.Anti-MuSK myasthenia gravis presenting with Epstein-Barr virus-associated mononucleosis and immune-mediated diabetes mellitus[J].Muscle Nerve,2007,36(2):264-266.
[14] 刘爱东.补体变化和重症肌无力病情的关系[D].第四军医大学,2009.
[15] Tuzu N E,Christadoss P.Complement associated pathogenic mechanisms in myasthenia gravis[J].Autoimmun Rev,2013,12(9):904-911.
[16] Huda R,Tuzun E,Christadoss P.Targeting complement system to treat myasthenia gravis[J].Rev Neurosci,2014,25(4):575-583.
[17] Warburton DER,Bredin SSD.Health benefits of physical activity:a systematic review of current systematic reviews[J].Curr Opin Cardiol,2017,32(5):541-556.
[18] Fregonezi GA,Resqueti VR,Guell R,et al.Effects of 8-week,interval-based inspiratory muscle training and breathing retraining in patients with generalized myasthenia gravis[J].Chest,2005,128(3):1524-1530.
[19] Nemr NK,Simoes-zenari M,Ferreira TS,et al.Dysphonia as the primary complaint in a case of myasthenia gravis:diagnosis and speech therapy[J].Codas,2013,25(3):297-300.